Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer

Umberto Pacetti, Enzo Veltri, Silvia Ileana Sara Fattoruso, Francesca D assisi Cardillo, Salvatore Evangelista, Francesco Cognetti, Alessandra Fabi

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To evaluate the efficacy of reduction of dexamethasone with a single-dose of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) for early breast cancer. Patients and methods: Chemotherapy-naive patients with breast cancer were given HEC in an adjuvant or neoadjuvant setting. Palonosetron and dexamethasone 4 mg i.v. were given on day 1 and another two administrations of dexamethasone 4 mg i.m. were given on days 2 and 3. The end-point was complete response (CR) and complete control (CC) during the acute and delayed phases. Results: Twenty-six patients were observed. Complete response was achieved in 19 out of 26 patients (72.4%); the same result was shown in 72.4% out of 76 courses given. Conclusion: This alternative schedule suggests efficacy for the control of acute and delayed emesis in moderately emetogenic chemotherapy. Further investigations are required to confirm these results.

Original languageEnglish
Pages (from-to)1721-1724
Number of pages4
JournalAnticancer Research
Volume33
Issue number4
Publication statusPublished - Apr 2013

Keywords

  • Dexamethasone
  • Early breast cancer
  • Palonosetron

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer'. Together they form a unique fingerprint.

Cite this